Who is sponsoring NCT05145686?

NCT05145686 is sponsored by Ege University.

What drugs are being tested in NCT05145686?

Interventions in NCT05145686: Matris metalloproteinase -2, -8, -9 expressions.

What condition does NCT05145686 study?

NCT05145686 studies Reversible Pulpitis.

Is NCT05145686 still recruiting?

NCT05145686 is currently completed. Last updated 3 January 2022.

Last reviewed 2022-01-03 · How we verify

NCT05145686

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Role of Matrix Metalloproteinases on the Primary Teeth Pulpotomy Treatments

Completed Phase 1, PHASE2 Last updated 3 January 2022

What this trial tests

Phase 1, PHASE2 trial testing Matris metalloproteinase -2, -8, -9 expressions in Reversible Pulpitis in 57 participants. Completed in 1 December 2019.

Timeline

1 January 2018

Primary endpoint
1 July 2019

1 December 2019

Quick facts

Lead sponsor	Ege University
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	57
Start date	1 January 2018
Primary completion	1 July 2019
Estimated completion	1 December 2019
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Matris metalloproteinase -2, -8, -9 expressions

Conditions studied

Reversible Pulpitis — all drugs for Reversible Pulpitis →

Sponsor

Ege University

Who can join

Adults 5 to 10, any sex, with Reversible Pulpitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Matrix metalloproteinases (MMPs) are important zinc enzyme group that responsible for reducing extracellular matrix components. It has been reported that MMPs play an important role in pulpal inflammation. The aims of this in vivo study was to compare the expression levels of MMP-2, -8 and -9 in primary molars with reversible and irreversible pulpitis and to compare the clinically and radiographically success of MTA and Biodentine materials at the end of 18 months.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Assessment of MMP levels in reversible and irreversible pulpitis and a randomized controlled trial comparing clinical success of two different calcium-silicate cements in pulpotomy treatment of primary molars with an 18-month follow-up.
Gerihan HE, Çoğulu D, Önçağ Ö, Durmaz A, et al · · 2024 · cited 3× · PMID 39215293 · DOI 10.1186/s12903-024-04795-5

Verify or expand the search:

Other recruiting trials for Reversible Pulpitis

Currently open trials in the same condition.

NCT07073573 — Evaluation of Pulpal Biomarkers in Vital Pulp Therapy · NA · active not recruiting
NCT07391124 — In Vivo Pulp Thermal Changes During Different Slenderization Techniques · NA · active not recruiting
NCT06844448 — The Effect of Different Risk Factors on the Success Rate of VPT · recruiting
NCT06433297 — Comparative Evaluation of Indirect vs. Direct Pulp Capping in Deep Carious Mandibular Molars · NA · recruiting
NCT07101068 — Assessment of Pain and Anxiety During Infiltration Anesthesia Using Dental Anesthesia Injector Versus Conventional Syrin · NA · recruiting

Other Ege University trials

Trials by the same sponsor.

NCT07468227 — Effect of Helfer Skin Tap and Vibration on Pain and Fear in Children During Intramuscular Injection · NA · not yet recruiting
NCT07473050 — Virtual Reality-Based 'Health at My Feet' Program for Individuals With Type 2 Diabetes · NA · not yet recruiting
NCT06955338 — Music and VR Effects on Pain, Anxiety, and Fear During Oral Mucositis Care in Leukaemic Children · NA · not yet recruiting
NCT07344532 — Effect of Preoperative Abdominal Effleurage on Postoperative Constipation · NA · not yet recruiting
NCT07417748 — Kinesthetic Exercises on Adults · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05145686 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ege University
Last refreshed: 3 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05145686.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing